Ola Melin

Chief Operating Officer at CIRCIO HOLDING ASA

Health Technology

Consumer Services

Profile

Ola Melin is currently the Chief Operating Officer at Circio Holding ASA. Prior to this role, she worked as the Director of Technical Operations at OxThera AB and as the Director of Extended Manufacturing at Swedish Orphan Biovitrum AB.
Ms. Melin completed her undergraduate degree at Mälardalen University.

Ola Melin active positions

Companies	Position	Start
CIRCIO HOLDING ASA	Chief Operating Officer	-

All active positions of Ola Melin

Former positions of Ola Melin

Companies	Position	End
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Chief Tech/Sci/R&D Officer	-
SWEDISH ORPHAN BIOVITRUM AB	Corporate Officer/Principal	-

See the detail of Ola Melin's experience

Training of Ola Melin

Mälardalen University

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ola Melin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
SWEDISH ORPHAN BIOVITRUM AB	Health Technology
CIRCIO HOLDING ASA	Health Technology

Private companies	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology